Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
| Revenue (TTM) | $324.97M |
| Gross Profit (TTM) | $157.29M |
| EBITDA | $-259.60M |
| Operating Margin | -52.30% |
| Return on Equity | -40.40% |
| Return on Assets | -20.30% |
| Revenue/Share (TTM) | $0.79 |
| Book Value | $1.63 |
| Price-to-Book | 4.38 |
| Price-to-Sales (TTM) | 9.73 |
| EV/Revenue | 9.53 |
| EV/EBITDA | -8.68 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 65.70% |
| Shares Outstanding | $452.97M |
| Float | $394.36M |
| % Insiders | 0.34% |
| % Institutions | 70.73% |
Volatility is currently expanding
Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.
The mean of analysts' price targets for Iovance Biotherapeutics (IOVA) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Iovance Biotherapeutics NASDAQ: IOVA reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic cancers.
Iovance Biotherapeutics is rated a buy, driven by strong Q2 results, surging Amtagvi sales, and promising pipeline catalysts. Q2 product revenues reached $99M, 10% above management guidance, with gross margin at 56% and a net loss of $(47.3m), beating consensus. IOVA's pipeline includes frontline melanoma and NSCLC, with key data presentations at ESMO and a BLA submission for NSCLC planned next year.
Iovance Biotherapeutics, Inc. (IOVA) Q2 2026 Earnings Call Transcript
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.33 per share a year ago.
U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter 2026 financial results, business achievements, and corporate updates.
Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN CARLOS, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, August 6, 2026 at 8:30 a.m.
SAN CARLOS, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 16, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 139,930 shares of Iovance's common stock to seventeen new, non-executive employees.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IOVA and any ticker you trade — then tracks every position and per-strategy win rate.
